PE61899A1 - Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico - Google Patents

Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico

Info

Publication number
PE61899A1
PE61899A1 PE1998000177A PE00017798A PE61899A1 PE 61899 A1 PE61899 A1 PE 61899A1 PE 1998000177 A PE1998000177 A PE 1998000177A PE 00017798 A PE00017798 A PE 00017798A PE 61899 A1 PE61899 A1 PE 61899A1
Authority
PE
Peru
Prior art keywords
composition
mixtures
conservative
ionic
prostaglandine
Prior art date
Application number
PE1998000177A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE61899(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE61899A1 publication Critical patent/PE61899A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE1998000177A 1997-03-17 1998-03-13 Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico PE61899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
PE61899A1 true PE61899A1 (es) 1999-06-30

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000177A PE61899A1 (es) 1997-03-17 1998-03-13 Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico

Country Status (32)

Country Link
EP (1) EP0969846B2 (https=)
JP (2) JP4920124B2 (https=)
KR (1) KR100555818B1 (https=)
CN (1) CN1236775C (https=)
AR (2) AR002194A1 (https=)
AT (1) ATE257385T1 (https=)
AU (1) AU738781B2 (https=)
BR (2) BR9808016A (https=)
CA (1) CA2280089C (https=)
CL (1) CL2009001870A1 (https=)
CO (1) CO4940427A1 (https=)
CY (1) CY2526B1 (https=)
CZ (1) CZ299833B6 (https=)
DE (1) DE69820997T3 (https=)
DK (1) DK0969846T4 (https=)
EE (1) EE04091B1 (https=)
ES (1) ES2214706T5 (https=)
HU (1) HU228896B1 (https=)
ID (1) ID22389A (https=)
IL (1) IL131041A0 (https=)
MY (1) MY122237A (https=)
NO (1) NO327713B1 (https=)
NZ (1) NZ337322A (https=)
PE (1) PE61899A1 (https=)
PL (1) PL197509B1 (https=)
PT (1) PT969846E (https=)
RU (1) RU2197970C2 (https=)
SI (1) SI0969846T2 (https=)
TW (1) TW527187B (https=)
UA (1) UA63938C2 (https=)
WO (1) WO1998041208A1 (https=)
ZA (1) ZA982188B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
WO2005089755A1 (en) * 2004-03-18 2005-09-29 R-Tech Ueno, Ltd. Aqueous composition comprising thiazole derivative
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
CN101400354B (zh) * 2006-03-13 2014-10-22 株式会社·R-技术上野 水性组合物
KR101454674B1 (ko) * 2006-03-17 2014-10-27 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
RU2465898C2 (ru) * 2006-10-31 2012-11-10 Алькон Рисерч, Лтд. Модуляторы связывания pai-1 для лечения глазных болезней
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
NZ584275A (en) * 2007-10-08 2012-06-29 Fovea Pharmaceuticals Aqueous cyclosporine ophthalmic formulations
ES2638771T3 (es) * 2008-03-17 2017-10-24 Novartis Ag Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
CA2858574C (en) 2011-12-07 2017-05-30 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
NZ732058A (en) 2014-11-25 2023-06-30 Allergan Inc Stabilized omega-3 ophthalmic compositions
AU2019343188A1 (en) * 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
AU2020272127B2 (en) 2019-04-12 2022-12-08 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69100171T2 (de) * 1990-05-22 1993-10-28 Ueno Seiyaku Oyo Kenkyujo Kk Synergistische Kombination zur ophthalmischen Verwendung.
WO1992013836A1 (en) * 1991-02-07 1992-08-20 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
EP0708646A1 (en) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
CA2280089C (en) 2009-03-03
HUP0002194A2 (hu) 2000-12-28
CN1249687A (zh) 2000-04-05
EP0969846B2 (en) 2010-08-25
DE69820997D1 (de) 2004-02-12
TW527187B (en) 2003-04-11
HK1026841A1 (en) 2000-12-29
JP2010043110A (ja) 2010-02-25
DE69820997T3 (de) 2011-10-06
NZ337322A (en) 2001-05-25
ATE257385T1 (de) 2004-01-15
SI0969846T2 (sl) 2010-12-31
CA2280089A1 (en) 1998-09-24
JP4920124B2 (ja) 2012-04-18
SI0969846T1 (en) 2004-06-30
PL197509B1 (pl) 2008-04-30
DE69820997T2 (de) 2004-12-09
KR20000076330A (ko) 2000-12-26
EE04091B1 (et) 2003-08-15
EP0969846A1 (en) 2000-01-12
UA63938C2 (uk) 2004-02-16
CZ299833B6 (cs) 2008-12-10
AR011192A1 (es) 2000-08-02
AR002194A1 (es) 1998-01-07
CY2526B1 (en) 2006-02-08
NO994481L (no) 1999-09-16
ID22389A (id) 1999-10-07
WO1998041208A1 (en) 1998-09-24
AU738781B2 (en) 2001-09-27
NO994481D0 (no) 1999-09-16
KR100555818B1 (ko) 2006-03-03
ES2214706T3 (es) 2004-09-16
MY122237A (en) 2006-04-29
JP2001515502A (ja) 2001-09-18
DK0969846T4 (da) 2010-12-20
BRPI9816218B1 (pt) 2016-04-12
AU7035398A (en) 1998-10-12
CZ325799A3 (cs) 2000-01-12
HUP0002194A3 (en) 2012-08-28
ES2214706T5 (es) 2011-02-02
PT969846E (pt) 2004-05-31
BR9808016A (pt) 2000-03-08
NO327713B1 (no) 2009-09-14
RU2197970C2 (ru) 2003-02-10
CO4940427A1 (es) 2000-07-24
CN1236775C (zh) 2006-01-18
ZA982188B (en) 1998-09-17
EP0969846B1 (en) 2004-01-07
IL131041A0 (en) 2001-01-28
CL2009001870A1 (es) 2010-01-22
HU228896B1 (en) 2013-06-28
PL335168A1 (en) 2000-04-10
DK0969846T3 (da) 2004-04-13
EE9900410A (et) 2000-04-17

Similar Documents

Publication Publication Date Title
PE61899A1 (es) Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico
RU2009116609A (ru) Система доставки с контролируемым высвобождением для назального применения нейротрансмиттеров
ES2188607T3 (es) Composiciones enzimaticas liquidas estabilizadas.
KR890000098A (ko) 세포 및 조직 수복제
HRP20170769T1 (hr) Postupak i pripravak za liječenje očne hipertenzije i glaukoma
LU90837I2 (fr) Sonovue-hexaflorure et ses d-riv-s pharmaceutiquement acceptables
CO5011119A1 (es) Jarabe antihistaminico estabilizado
ES8205855A1 (es) Un procedimiento para la preparacion y estabilizacion de una composicion blanqueante acuosa que contiene peroxido de hi-drogeno.
RU94046143A (ru) Фармацевтическая композиция для лечения глаукомы
AR010288A1 (es) Composicion micobactericida concentrada acuosa; composicion desinfectante de superficies duras y metodo de desinfeccion de una superficie dura
DE60104872D1 (de) Stabilisierte ophthalmische wasserstoffperoxidlösung
DK0572190T3 (da) Oftalmiske præparater indeholdende vitamin E eller en ester deraf som en aktiv ingrediens
RU2004129593A (ru) Офтальмическая композиция, содержащая аскомицин
KR900002789A (ko) 안과용 용액을 보존하는 방법 및 이를 위한 조성물
RU2002103315A (ru) Офтальмическая композиция, содержащая кетотифен
AR247804A1 (es) Composicion biocida sinergica y metodo para proteger con la misma composiciones industriales
KR960706472A (ko) 프로스타글란딘 유도체, 그의 염 및 그의 사용
AR017925A1 (es) Una formulacion acuosa para verter, topicamente aceptable, adaptada para su aplicacion externa localizada en un animal, su uso y un metodo para formularla
ATE85031T1 (de) Stabilisierung von wasserstoffperoxid.
ES500581A0 (es) Un procedimiento para la preparacion de una composicion detergente blanqueadora, del tipo que genera peracidos organicos
ATE150764T1 (de) Alkylester von oxidiertem glutathion
ES2022448B3 (es) Composicion desinfectante para lentes de contacto blandas, que contienen una disolucion de peroxido de hidrogeno estabilizada.
FR2790953B1 (fr) Composition a phase aqueuse continue renfermant de l'acide l-2-oxothiazolidine 4-carboxylique
ES2163528T3 (es) Una solucion acuosa para infusion, estable al almacenamiento, que contiene un inhibidor de trombina.
SE8705064D0 (sv) Emulsion for parenteral administrering

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed